Item 7.01. Regulation FD Disclosures.
On November 16, 2026, MetaVia Inc. (the “Company”) issued a press release announcing positive preclinical data from a head-to-head study comparing DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, with retatrutide, a triple GLP1R/GIPR/GCGR agonist. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated herein by reference.
The information in Item 7.01 of this Report, including Exhibit 99.1 attached hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release are as inactive textual references only.
Item 8.01. Other Events.
On November 14, 2026, the Company presented positive preclinical data from a head-to-head study comparing DA-1726, a novel dual OXM analog targeting both GLP1R and GCGR, with retatrutide, a triple GLP1R/GIPR/GCGR agonist.
The study evaluated DA-1726 and retatrutide in diet-induced obese mice, assessing body weight, food intake, body composition, plasma metabolic parameters and thermogenesis-related gene expression. Animals received twice-weekly subcutaneous injections of DA-1726 at 300 or 500 nmol/kg or retatrutide at 100 or 200 nmol/kg for approximately three weeks. The higher doses were selected based on pharmacokinetic exposure estimates intended to approximate clinical exposures at 48 mg for DA-1726 and 12 mg for retatrutide.
DA-1726 demonstrated increased hepatic expression of fibroblast growth factor 21 (Fgf21) along with increased liver FGF21 protein and a numerical increase in circulating FGF21 at the higher dose. DA-1726 also induced greater expression of genes associated with brown adipose tissue thermogenesis and white adipose tissue browning compared with retatrutide. At the higher dose, expression of thermogenesis-related genes, including Ucp1, Ppargc1a and Fgf21, was increased in brown and inguinal white adipose tissue, with several markers demonstrating significantly greater expression than observed with high-dose retatrutide. These findings suggest that glucagon receptor-associated metabolic pathways, including those involving FGF21 and thermogenesis, may contribute to DA-1726’s weight-loss effects.
DA-1726 also demonstrated greater glucose lowering compared with retatrutide, along with favorable effects on lipid metabolism. Plasma glucose levels decreased by 43.0% and 39.2% at the low and high doses, respectively, compared with reductions of 21.5% and 32.5% for retatrutide. Both compounds demonstrated improvements in plasma lipid parameters, with DA-1726 reducing total cholesterol by 70.9% and 69.3%, compared with 60.9% and 69.0% for retatrutide, and LDL cholesterol by 89.9% and 88.4%, compared with 82.8% and 88.1% for retatrutide, respectively. These results demonstrated comparable or numerically greater improvements in glucose and lipid parameters with DA-1726.
In addition, DA-1726 achieved weight loss comparable to retatrutide despite less suppression of food intake. After adjustment relative to the diet-induced obese control group, DA-1726 achieved body weight reductions of 34.2% and 41.7% at the low and high doses, respectively, compared with reductions of 33.7% and 43.6% for retatrutide. However, DA-1726 reduced food intake by 19.6% and 31.2%, compared with 36.7% and 41.4% for retatrutide, respectively. Both treatments also demonstrated comparable effects on body composition, including substantial reductions in fat mass. These findings suggest a potentially greater contribution of glucagon receptor-associated energy expenditure to weight loss with DA-1726 than with retatrutide.
Forward-Looking Statements
This Report, including Exhibit 99.1 attached hereto, contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports that the Company has filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.